Edesa Biotech (EDSA) Competitors $2.10 +0.02 (+0.72%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. CUE, TELO, INMB, IZTC, UNCY, VRCA, HOWL, IFRX, ICCC, and ATHEShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Cue Biopharma (CUE), Telomir Pharmaceuticals (TELO), INmune Bio (INMB), Invizyne Technologies (IZTC), Unicycive Therapeutics (UNCY), Verrica Pharmaceuticals (VRCA), Werewolf Therapeutics (HOWL), InflaRx (IFRX), ImmuCell (ICCC), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors Cue Biopharma Telomir Pharmaceuticals INmune Bio Invizyne Technologies Unicycive Therapeutics Verrica Pharmaceuticals Werewolf Therapeutics InflaRx ImmuCell Alterity Therapeutics Cue Biopharma (NASDAQ:CUE) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Does the media favor CUE or EDSA? In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Cue Biopharma's average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in CUE or EDSA? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 10.8% of Cue Biopharma shares are owned by insiders. Comparatively, 22.6% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, CUE or EDSA? Edesa Biotech has lower revenue, but higher earnings than Cue Biopharma. Edesa Biotech is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.29M6.81-$40.67M-$0.67-1.25Edesa BiotechN/AN/A-$6.17M-$1.59-1.32 Do analysts rate CUE or EDSA? Cue Biopharma currently has a consensus target price of $4.00, indicating a potential upside of 376.19%. Edesa Biotech has a consensus target price of $5.00, indicating a potential upside of 137.53%. Given Cue Biopharma's higher possible upside, equities analysts clearly believe Cue Biopharma is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is CUE or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to Cue Biopharma's net margin of -507.87%. Edesa Biotech's return on equity of -187.01% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-507.87% -228.43% -114.66% Edesa Biotech N/A -187.01%-78.72% Which has more risk & volatility, CUE or EDSA? Cue Biopharma has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. SummaryCue Biopharma and Edesa Biotech tied by winning 7 of the 14 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.80M$2.98B$5.44B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-1.3218.0530.0425.06Price / SalesN/A175.18373.4277.08Price / CashN/A41.8335.9458.58Price / Book3.457.218.125.67Net Income-$6.17M-$54.43M$3.25B$265.39M7 Day Performance-1.64%0.07%0.96%2.54%1 Month Performance2.68%5.29%2.69%1.89%1 Year Performance-56.05%9.94%28.08%24.09% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech1.365 of 5 stars$2.11+0.7%$5.00+137.5%-56.5%$14.80MN/A-1.3220Gap UpCUECue Biopharma3.8572 of 5 stars$0.82-7.1%$4.00+387.6%+19.1%$66.53M$9.29M-1.2260News CoverageUpcoming EarningsTELOTelomir Pharmaceuticals2.9223 of 5 stars$2.10-4.1%$15.00+614.3%-58.0%$65.18MN/A-5.001News CoverageUpcoming EarningsINMBINmune Bio2.3607 of 5 stars$2.91+7.4%$18.40+532.3%-60.4%$63.92M$50K-1.5110Earnings ReportGap DownIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpUNCYUnicycive Therapeutics2.3928 of 5 stars$4.71-3.3%$60.00+1,173.9%+16.8%$61.56M$680K-0.929VRCAVerrica Pharmaceuticals4.0117 of 5 stars$6.79+2.7%$80.00+1,078.2%-88.3%$61.14M$7.57M-0.5740Upcoming EarningsHOWLWerewolf Therapeutics3.8055 of 5 stars$1.35-0.7%$8.33+517.3%-31.0%$61.03M$1.88M-0.8140News CoverageUpcoming EarningsIFRXInflaRx3.2596 of 5 stars$0.88-2.4%$6.60+652.7%-41.8%$60.33M$180K-1.0760News CoverageICCCImmuCell0.0628 of 5 stars$6.70+1.3%N/A+63.7%$59.74M$26.49M-95.6970News CoverageUpcoming EarningsATHEAlterity Therapeutics1.7382 of 5 stars$5.58-14.8%$12.00+115.1%+308.5%$58.08MN/A0.0010Gap DownHigh Trading Volume Related Companies and Tools Related Companies CUE Competitors TELO Competitors INMB Competitors IZTC Competitors UNCY Competitors VRCA Competitors HOWL Competitors IFRX Competitors ICCC Competitors ATHE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
